News by Subject Medicine & Health

A recent survey from the GW School of Medicine and Health Sciences found patients with psoriasis frequently use complementary or alternative therapies to treat their symptoms when traditional treatments fail.

A nationwide phase II clinical trial, coordinated out of Tufts Medical Center in Boston, has found that a topical cream was extremely effective in reversing the effects of vitiligo, a relatively common autoimmune disease that causes loss of skin pigmentation. Topical application of the medicated cream, ruxolitinib, which is currently used as an oral treatment for certain blood disorders, resulted in substantial improvement of facial vitiligo symptoms in nearly half of the trial's participants.

The results of a phase 2B study presented today at the Annual European Congress of Rheumatology (EULAR 2019) demonstrate superior efficacy and comparable safety of tildrakizumab versus placebo in patients with psoriatic arthritis.

The results of a study presented today at the Annual European Congress of Rheumatology (EULAR 2019) suggest that overall cancer risk is not linked to tumor necrosis factor inhibitor (TNFi) use in psoriatic arthritis.

The results of a study presented today at the Annual European Congress of Rheumatology (EULAR 2019) demonstrate significant correlation between body mass index (BMI) and disease severity in psoriatic arthritis.

Burt's Bees, a leading provider of personal care products committed to natural skin care solutions, today announced research supporting new findings related to the skin's composition and the role of nature-based regimens to protect the skin against common environmental stressors. The studies will be presented at the 24th World Congress of Dermatology (WCD) Meeting in Milan, Italy, June 10-15, 2019.

A third of eczema management mobile applications provide information that does not agree with international treatment and condition guidelines, a study led by Nanyang Technological University, Singapore (NTU Singapore) has found. The study, published online this week in the British Journal of Dermatology, highlights the need for mechanisms and guidelines to ensure app quality, and to guide personalised app selection for patients, caregivers and doctors.